Duodenal alpha‐Synuclein Pathology and Enteric Gliosis in Advanced Parkinson's Disease

Background The role of the gut‐brain axis has been recently highlighted as a major contributor to Parkinson's disease (PD) physiopathology, with numerous studies investigating bidirectional transmission of pathological protein aggregates, such as α‐synuclein (αSyn). However, the extent and the...

Full description

Saved in:
Bibliographic Details
Published inMovement disorders Vol. 38; no. 5; pp. 885 - 894
Main Authors Emmi, Aron, Sandre, Michele, Russo, Francesco Paolo, Tombesi, Giulia, Garrì, Federica, Campagnolo, Marta, Carecchio, Miryam, Biundo, Roberta, Spolverato, Gaya, Macchi, Veronica, Savarino, Edoardo, Farinati, Fabio, Parchi, Piero, Porzionato, Andrea, Bubacco, Luigi, De Caro, Raffaele, Kovacs, Gabor G., Antonini, Angelo
Format Journal Article
LanguageEnglish
Published Hoboken, USA John Wiley & Sons, Inc 01.05.2023
Wiley Subscription Services, Inc
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Background The role of the gut‐brain axis has been recently highlighted as a major contributor to Parkinson's disease (PD) physiopathology, with numerous studies investigating bidirectional transmission of pathological protein aggregates, such as α‐synuclein (αSyn). However, the extent and the characteristics of pathology in the enteric nervous system have not been fully investigated. Objective We characterized αSyn alterations and glial responses in duodenum biopsies of patients with PD by employing topography‐specific sampling and conformation‐specific αSyn antibodies. Methods We examined 18 patients with advanced PD who underwent Duodopa percutaneous endoscopic gastrostomy and jejunal tube procedure, 4 untreated patients with early PD (disease duration <5 years), and 18 age‐ and ‐sex‐matched healthy control subjects undergoing routine diagnostic endoscopy. A mean of four duodenal wall biopsies were sampled from each patient. Immunohistochemistry was performed for anti‐aggregated αSyn (5G4) and glial fibrillary acidic protein antibodies. Morphometrical semiquantitative analysis was performed to characterize αSyn‐5G4+ and glial fibrillary acidic protein–positive density and size. Results Immunoreactivity for aggregated α‐Syn was identified in all patients with PD (early and advanced) compared with controls. αSyn‐5G4+ colocalized with neuronal marker β‐III‐tubulin. Evaluation of enteric glial cells demonstrated an increased size and density when compared with controls, suggesting reactive gliosis. Conclusions We found evidence of synuclein pathology and gliosis in the duodenum of patients with PD, including early de novo cases. Future studies are required to evaluate how early in the disease process duodenal pathology occurs and its possible contribution to levodopa effect in chronic patients. © 2023 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
AbstractList The role of the gut-brain axis has been recently highlighted as a major contributor to Parkinson's disease (PD) physiopathology, with numerous studies investigating bidirectional transmission of pathological protein aggregates, such as α-synuclein (αSyn). However, the extent and the characteristics of pathology in the enteric nervous system have not been fully investigated. We characterized αSyn alterations and glial responses in duodenum biopsies of patients with PD by employing topography-specific sampling and conformation-specific αSyn antibodies. We examined 18 patients with advanced PD who underwent Duodopa percutaneous endoscopic gastrostomy and jejunal tube procedure, 4 untreated patients with early PD (disease duration <5 years), and 18 age- and -sex-matched healthy control subjects undergoing routine diagnostic endoscopy. A mean of four duodenal wall biopsies were sampled from each patient. Immunohistochemistry was performed for anti-aggregated αSyn (5G4) and glial fibrillary acidic protein antibodies. Morphometrical semiquantitative analysis was performed to characterize αSyn-5G4 and glial fibrillary acidic protein-positive density and size. Immunoreactivity for aggregated α-Syn was identified in all patients with PD (early and advanced) compared with controls. αSyn-5G4 colocalized with neuronal marker β-III-tubulin. Evaluation of enteric glial cells demonstrated an increased size and density when compared with controls, suggesting reactive gliosis. We found evidence of synuclein pathology and gliosis in the duodenum of patients with PD, including early de novo cases. Future studies are required to evaluate how early in the disease process duodenal pathology occurs and its possible contribution to levodopa effect in chronic patients. © 2023 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
BackgroundThe role of the gut‐brain axis has been recently highlighted as a major contributor to Parkinson's disease (PD) physiopathology, with numerous studies investigating bidirectional transmission of pathological protein aggregates, such as α‐synuclein (αSyn). However, the extent and the characteristics of pathology in the enteric nervous system have not been fully investigated.ObjectiveWe characterized αSyn alterations and glial responses in duodenum biopsies of patients with PD by employing topography‐specific sampling and conformation‐specific αSyn antibodies.MethodsWe examined 18 patients with advanced PD who underwent Duodopa percutaneous endoscopic gastrostomy and jejunal tube procedure, 4 untreated patients with early PD (disease duration <5 years), and 18 age‐ and ‐sex‐matched healthy control subjects undergoing routine diagnostic endoscopy. A mean of four duodenal wall biopsies were sampled from each patient. Immunohistochemistry was performed for anti‐aggregated αSyn (5G4) and glial fibrillary acidic protein antibodies. Morphometrical semiquantitative analysis was performed to characterize αSyn‐5G4+ and glial fibrillary acidic protein–positive density and size.ResultsImmunoreactivity for aggregated α‐Syn was identified in all patients with PD (early and advanced) compared with controls. αSyn‐5G4+ colocalized with neuronal marker β‐III‐tubulin. Evaluation of enteric glial cells demonstrated an increased size and density when compared with controls, suggesting reactive gliosis.ConclusionsWe found evidence of synuclein pathology and gliosis in the duodenum of patients with PD, including early de novo cases. Future studies are required to evaluate how early in the disease process duodenal pathology occurs and its possible contribution to levodopa effect in chronic patients. © 2023 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
The role of the gut-brain axis has been recently highlighted as a major contributor to Parkinson's disease (PD) physiopathology, with numerous studies investigating bidirectional transmission of pathological protein aggregates, such as α-synuclein (αSyn). However, the extent and the characteristics of pathology in the enteric nervous system have not been fully investigated.BACKGROUNDThe role of the gut-brain axis has been recently highlighted as a major contributor to Parkinson's disease (PD) physiopathology, with numerous studies investigating bidirectional transmission of pathological protein aggregates, such as α-synuclein (αSyn). However, the extent and the characteristics of pathology in the enteric nervous system have not been fully investigated.We characterized αSyn alterations and glial responses in duodenum biopsies of patients with PD by employing topography-specific sampling and conformation-specific αSyn antibodies.OBJECTIVEWe characterized αSyn alterations and glial responses in duodenum biopsies of patients with PD by employing topography-specific sampling and conformation-specific αSyn antibodies.We examined 18 patients with advanced PD who underwent Duodopa percutaneous endoscopic gastrostomy and jejunal tube procedure, 4 untreated patients with early PD (disease duration <5 years), and 18 age- and -sex-matched healthy control subjects undergoing routine diagnostic endoscopy. A mean of four duodenal wall biopsies were sampled from each patient. Immunohistochemistry was performed for anti-aggregated αSyn (5G4) and glial fibrillary acidic protein antibodies. Morphometrical semiquantitative analysis was performed to characterize αSyn-5G4+ and glial fibrillary acidic protein-positive density and size.METHODSWe examined 18 patients with advanced PD who underwent Duodopa percutaneous endoscopic gastrostomy and jejunal tube procedure, 4 untreated patients with early PD (disease duration <5 years), and 18 age- and -sex-matched healthy control subjects undergoing routine diagnostic endoscopy. A mean of four duodenal wall biopsies were sampled from each patient. Immunohistochemistry was performed for anti-aggregated αSyn (5G4) and glial fibrillary acidic protein antibodies. Morphometrical semiquantitative analysis was performed to characterize αSyn-5G4+ and glial fibrillary acidic protein-positive density and size.Immunoreactivity for aggregated α-Syn was identified in all patients with PD (early and advanced) compared with controls. αSyn-5G4+ colocalized with neuronal marker β-III-tubulin. Evaluation of enteric glial cells demonstrated an increased size and density when compared with controls, suggesting reactive gliosis.RESULTSImmunoreactivity for aggregated α-Syn was identified in all patients with PD (early and advanced) compared with controls. αSyn-5G4+ colocalized with neuronal marker β-III-tubulin. Evaluation of enteric glial cells demonstrated an increased size and density when compared with controls, suggesting reactive gliosis.We found evidence of synuclein pathology and gliosis in the duodenum of patients with PD, including early de novo cases. Future studies are required to evaluate how early in the disease process duodenal pathology occurs and its possible contribution to levodopa effect in chronic patients. © 2023 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.CONCLUSIONSWe found evidence of synuclein pathology and gliosis in the duodenum of patients with PD, including early de novo cases. Future studies are required to evaluate how early in the disease process duodenal pathology occurs and its possible contribution to levodopa effect in chronic patients. © 2023 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
Background The role of the gut‐brain axis has been recently highlighted as a major contributor to Parkinson's disease (PD) physiopathology, with numerous studies investigating bidirectional transmission of pathological protein aggregates, such as α‐synuclein (αSyn). However, the extent and the characteristics of pathology in the enteric nervous system have not been fully investigated. Objective We characterized αSyn alterations and glial responses in duodenum biopsies of patients with PD by employing topography‐specific sampling and conformation‐specific αSyn antibodies. Methods We examined 18 patients with advanced PD who underwent Duodopa percutaneous endoscopic gastrostomy and jejunal tube procedure, 4 untreated patients with early PD (disease duration <5 years), and 18 age‐ and ‐sex‐matched healthy control subjects undergoing routine diagnostic endoscopy. A mean of four duodenal wall biopsies were sampled from each patient. Immunohistochemistry was performed for anti‐aggregated αSyn (5G4) and glial fibrillary acidic protein antibodies. Morphometrical semiquantitative analysis was performed to characterize αSyn‐5G4+ and glial fibrillary acidic protein–positive density and size. Results Immunoreactivity for aggregated α‐Syn was identified in all patients with PD (early and advanced) compared with controls. αSyn‐5G4+ colocalized with neuronal marker β‐III‐tubulin. Evaluation of enteric glial cells demonstrated an increased size and density when compared with controls, suggesting reactive gliosis. Conclusions We found evidence of synuclein pathology and gliosis in the duodenum of patients with PD, including early de novo cases. Future studies are required to evaluate how early in the disease process duodenal pathology occurs and its possible contribution to levodopa effect in chronic patients. © 2023 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
Author Carecchio, Miryam
Macchi, Veronica
Spolverato, Gaya
Antonini, Angelo
De Caro, Raffaele
Russo, Francesco Paolo
Tombesi, Giulia
Campagnolo, Marta
Garrì, Federica
Biundo, Roberta
Farinati, Fabio
Porzionato, Andrea
Kovacs, Gabor G.
Sandre, Michele
Savarino, Edoardo
Emmi, Aron
Parchi, Piero
Bubacco, Luigi
Author_xml – sequence: 1
  givenname: Aron
  orcidid: 0000-0002-2796-5676
  surname: Emmi
  fullname: Emmi, Aron
  organization: Center for Neurodegenerative Disease Research (CESNE), Department of Neuroscience, University of Padova
– sequence: 2
  givenname: Michele
  surname: Sandre
  fullname: Sandre, Michele
  organization: Center for Neurodegenerative Disease Research (CESNE), Department of Neuroscience, University of Padova
– sequence: 3
  givenname: Francesco Paolo
  surname: Russo
  fullname: Russo, Francesco Paolo
  organization: Padova University Hospital
– sequence: 4
  givenname: Giulia
  surname: Tombesi
  fullname: Tombesi, Giulia
  organization: University of Padova
– sequence: 5
  givenname: Federica
  surname: Garrì
  fullname: Garrì, Federica
  organization: University of Padova
– sequence: 6
  givenname: Marta
  orcidid: 0000-0002-6394-7168
  surname: Campagnolo
  fullname: Campagnolo, Marta
  organization: Center for Neurodegenerative Disease Research (CESNE), Department of Neuroscience, University of Padova
– sequence: 7
  givenname: Miryam
  surname: Carecchio
  fullname: Carecchio, Miryam
  organization: Center for Neurodegenerative Disease Research (CESNE), Department of Neuroscience, University of Padova
– sequence: 8
  givenname: Roberta
  surname: Biundo
  fullname: Biundo, Roberta
  organization: University of Padova
– sequence: 9
  givenname: Gaya
  surname: Spolverato
  fullname: Spolverato, Gaya
  organization: Padova University Hospital
– sequence: 10
  givenname: Veronica
  surname: Macchi
  fullname: Macchi, Veronica
  organization: Center for Neurodegenerative Disease Research (CESNE), Department of Neuroscience, University of Padova
– sequence: 11
  givenname: Edoardo
  surname: Savarino
  fullname: Savarino, Edoardo
  organization: Padova University Hospital
– sequence: 12
  givenname: Fabio
  surname: Farinati
  fullname: Farinati, Fabio
  organization: Padova University Hospital
– sequence: 13
  givenname: Piero
  orcidid: 0000-0002-9444-9524
  surname: Parchi
  fullname: Parchi, Piero
  organization: University of Bologna
– sequence: 14
  givenname: Andrea
  surname: Porzionato
  fullname: Porzionato, Andrea
  organization: Center for Neurodegenerative Disease Research (CESNE), Department of Neuroscience, University of Padova
– sequence: 15
  givenname: Luigi
  surname: Bubacco
  fullname: Bubacco, Luigi
  organization: University of Padova
– sequence: 16
  givenname: Raffaele
  surname: De Caro
  fullname: De Caro, Raffaele
  organization: Center for Neurodegenerative Disease Research (CESNE), Department of Neuroscience, University of Padova
– sequence: 17
  givenname: Gabor G.
  surname: Kovacs
  fullname: Kovacs, Gabor G.
  organization: Laboratory Medicine Program & Krembil Brain Institute, University Health Network
– sequence: 18
  givenname: Angelo
  surname: Antonini
  fullname: Antonini, Angelo
  email: angelo.antonini@unipd.it
  organization: Center for Neurodegenerative Disease Research (CESNE), Department of Neuroscience, University of Padova
BackLink https://www.ncbi.nlm.nih.gov/pubmed/36847308$$D View this record in MEDLINE/PubMed
BookMark eNp10c1OGzEUBWCrApUAXfQFqpG6KCwC9tgzc2eJCAUkEEiAxM5y_NM4dexgzxTNro_AM_IkGBI2qN3YXnznSr5nG2344DVCXwk-IBiXhwuVDsqWVvAJjUhFyRjKqtlAIwxQjSmBagttpzTHmJCK1J_RFq2BNRTDCN1P-qC0F64QbjkTz3-fbgbfS6etL65FNwsu_BoK4VVx4jsdrSxOnQ3JpiKDI_VHeKlVlvG39Sn4H6mY2KRF0rto0wiX9Jf1vYPufp7cHp-NL65Oz4-PLsaSAkA-VUOYNIIaPG0prltDWH4pQ2Da1AYYayvNJBXEsBKXBLBpdSukEjKzlu6gvdXcZQwPvU4dX9gktXPC69AnXjaAGVCGm0y_f6Dz0Mf896ygZFXTUKiz-rZW_XShFV9GuxBx4O87y-BwBWQMKUVtuLSd6GzwXRTWcYL5ays8t8LfWsmJ_Q-J96H_suvpj9bp4f-QX05uVokXQqCblg
CitedBy_id crossref_primary_10_1002_mdc3_70029
crossref_primary_10_3390_biom13081263
crossref_primary_10_1016_j_nbd_2024_106609
crossref_primary_10_1017_cjn_2023_291
crossref_primary_10_1111_nmo_14780
crossref_primary_10_1080_14656566_2023_2240228
crossref_primary_10_1101_cshperspect_a041618
crossref_primary_10_3390_ijms25010481
crossref_primary_10_1016_j_nbd_2023_106296
crossref_primary_10_3390_life14050559
crossref_primary_10_1016_j_parkreldis_2023_105956
crossref_primary_10_1016_j_neuroscience_2024_01_009
crossref_primary_10_3390_ijms24087205
crossref_primary_10_1038_s41531_024_00766_3
crossref_primary_10_1038_s41531_023_00554_5
crossref_primary_10_1002_acn3_52282
crossref_primary_10_3389_fphys_2024_1422270
crossref_primary_10_4103_NRR_NRR_D_24_00607
crossref_primary_10_1002_mdc3_13786
crossref_primary_10_1007_s10072_024_07467_y
crossref_primary_10_3390_ijms25021294
crossref_primary_10_1038_s41582_024_01034_x
crossref_primary_10_3389_fcimb_2023_1181315
crossref_primary_10_1007_s10072_023_07056_5
Cites_doi 10.1212/wnl.0000000000010404
10.1002/mds.26473
10.1155/2020/8024171
10.1002/mds.25776
10.1016/j.parkreldis.2020.08.020
10.1007/s00401-012-0964-x
10.1002/mds.27380
10.1007/bf02056950
10.1113/jp271021
10.1002/glia.22746
10.3389/fcell.2022.886604
10.1111/nan.12486
10.1111/nmo.13777
10.1002/mds.25979
10.1002/mds.25988
10.3233/JPD-191721
10.1016/j.jns.2021.119460
10.3389/fnins.2022.945574
10.1038/nrneurol.2015.197
10.1016/j.nbd.2014.05.020
10.1016/j.nbd.2020.105086
10.1016/j.neuron.2019.05.035
10.1007/s00415-012-6801-2
10.1172/jci143775
10.1155/2020/4687530
10.1212/wnl.0000000000001240
10.3389/fnana.2021.663399
10.14802/jmd.19046
10.1111/jnc.12742
10.3390/ijms21228666
10.3233/JPD-202481
10.1212/wnl.0000000000009107
10.1186/s40478-019-0787-2
10.1111/1556-4029.14497
10.3390/ijms21239199
10.1021/acschemneuro.8b00383
10.1186/s40478-016-0408-2
10.1172/jci76303
10.1002/ana.24648
10.1007/s12325-021-01747-1
10.1038/s41593-020-0589-7
ContentType Journal Article
Copyright 2023 The Authors. published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
2023 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
2023. This article is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Copyright_xml – notice: 2023 The Authors. published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
– notice: 2023 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
– notice: 2023. This article is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
DBID 24P
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7TK
8FD
FR3
K9.
NAPCQ
P64
RC3
7X8
DOI 10.1002/mds.29358
DatabaseName Wiley Online Library Open Access
CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
Neurosciences Abstracts
Technology Research Database
Engineering Research Database
ProQuest Health & Medical Complete (Alumni)
Nursing & Allied Health Premium
Biotechnology and BioEngineering Abstracts
Genetics Abstracts
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Nursing & Allied Health Premium
Genetics Abstracts
Technology Research Database
ProQuest Health & Medical Complete (Alumni)
Engineering Research Database
Neurosciences Abstracts
Biotechnology and BioEngineering Abstracts
MEDLINE - Academic
DatabaseTitleList MEDLINE
Nursing & Allied Health Premium
MEDLINE - Academic

Database_xml – sequence: 1
  dbid: 24P
  name: Wiley Online Library Open Access
  url: https://authorservices.wiley.com/open-science/open-access/browse-journals.html
  sourceTypes: Publisher
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1531-8257
EndPage 894
ExternalDocumentID 36847308
10_1002_mds_29358
MDS29358
Genre shortCommunication
Research Support, Non-U.S. Gov't
Journal Article
GroupedDBID ---
.3N
.GA
.GJ
.Y3
05W
0R~
10A
123
1CY
1L6
1OB
1OC
1ZS
24P
31~
33P
3PY
3SF
3WU
4.4
4ZD
50Y
50Z
51W
51X
52M
52N
52O
52P
52R
52S
52T
52U
52V
52W
52X
53G
5VS
66C
6PF
702
7PT
8-0
8-1
8-3
8-4
8-5
8UM
930
A01
A03
AAESR
AAEVG
AAHHS
AAHQN
AAIPD
AAMNL
AANHP
AANLZ
AAONW
AASGY
AAWTL
AAXRX
AAYCA
AAZKR
ABCQN
ABCUV
ABEML
ABIJN
ABJNI
ABLJU
ABPVW
ABQWH
ABXGK
ACAHQ
ACBWZ
ACCFJ
ACCZN
ACGFS
ACGOF
ACMXC
ACPOU
ACPRK
ACRPL
ACSCC
ACXBN
ACXQS
ACYXJ
ADBBV
ADBTR
ADEOM
ADIZJ
ADKYN
ADMGS
ADNMO
ADOZA
ADXAS
ADZMN
AEEZP
AEIGN
AEIMD
AENEX
AEQDE
AEUQT
AEUYR
AFBPY
AFFPM
AFGKR
AFPWT
AFWVQ
AFZJQ
AHBTC
AHMBA
AIACR
AITYG
AIURR
AIWBW
AJBDE
ALAGY
ALMA_UNASSIGNED_HOLDINGS
ALUQN
ALVPJ
AMBMR
AMYDB
ASPBG
ATUGU
AVWKF
AZBYB
AZFZN
AZVAB
BAFTC
BDRZF
BFHJK
BHBCM
BMXJE
BROTX
BRXPI
BY8
C45
CS3
D-6
D-7
D-E
D-F
DCZOG
DPXWK
DR1
DR2
DRFUL
DRMAN
DRSTM
DU5
EBD
EBS
EJD
EMOBN
F00
F01
F04
F5P
FEDTE
FUBAC
FYBCS
G-S
G.N
GNP
GODZA
H.X
HBH
HF~
HGLYW
HHY
HHZ
HVGLF
HZ~
IX1
J0M
JPC
KBYEO
KQQ
LATKE
LAW
LC2
LC3
LEEKS
LH4
LITHE
LOXES
LP6
LP7
LUTES
LW6
LYRES
M6M
MEWTI
MK4
MRFUL
MRMAN
MRSTM
MSFUL
MSMAN
MSSTM
MXFUL
MXMAN
MXSTM
N04
N05
N9A
NF~
NNB
O66
O9-
OIG
OVD
P2P
P2W
P2X
P2Z
P4B
P4D
PALCI
PQQKQ
Q.N
Q11
QB0
QRW
R.K
RIWAO
RJQFR
ROL
RWD
RWI
RX1
RYL
SAMSI
SUPJJ
SV3
TEORI
TWZ
UB1
V2E
V9Y
W8V
W99
WBKPD
WHWMO
WIB
WIH
WIJ
WIK
WJL
WOHZO
WQJ
WRC
WUP
WVDHM
WXI
WXSBR
XG1
XV2
YCJ
ZGI
ZZTAW
~IA
~WT
AAMMB
AAYXX
AEFGJ
AEYWJ
AGHNM
AGQPQ
AGXDD
AGYGG
AIDQK
AIDYY
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7TK
8FD
FR3
K9.
NAPCQ
P64
RC3
7X8
ID FETCH-LOGICAL-c3888-c3d714cfa3f0b93069f140b9df18b76f84495e4c3a1f4202180f9e9acdac0b993
IEDL.DBID DR2
ISSN 0885-3185
1531-8257
IngestDate Fri Jul 11 10:25:22 EDT 2025
Tue Aug 12 12:11:22 EDT 2025
Wed Feb 19 02:24:18 EST 2025
Thu Apr 24 23:04:08 EDT 2025
Sun Jul 06 05:01:59 EDT 2025
Wed Jan 22 16:20:28 EST 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 5
Keywords gastrointestinal biopsies
Parkinson's disease
enteric nervous system
alpha-synuclein
neuropathology
Language English
License Attribution-NonCommercial-NoDerivs
2023 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c3888-c3d714cfa3f0b93069f140b9df18b76f84495e4c3a1f4202180f9e9acdac0b993
Notes Full financial disclosures and author roles may be found in the online version of this article.
A.A. has received compensation for consultancy and speaker‐related activities from UCB, Boehringer Ingelheim, Ever Pharma, General Electric, Britannia, AbbVie, Kyowa Kirin, Zambon, Bial, Theravance Biopharma, Jazz Pharmaceuticals, Roche, and Medscape; has received research support from Bial, Lundbeck, Roche, Angelini Pharmaceuticals, Horizon 2020 Grants 825785 and 101016902, Ministry of Education University and Research Grant ARS01_01081, Cariparo Foundation, and Movement Disorders Society for NMS Scale validation; and has served as consultant for Boehringer–Ingelheim for legal cases on pathological gambling. G.G.K. has served as an advisor for Biogen; has received royalty for 5G4 synuclein antibody and publishing royalties from Wiley, Cambridge University Press, and Elsevier; has received grants from Edmond J. Safra Philanthropic Foundation, Rossy Family Foundation, The Michael J. Fox Foundation, Parkinson Canada, and Canada Foundation for Innovation. All other authors declare no conflict of interest.
Aron Emmi and Michele Sandre contributed equally to this work.
Relevant conflicts of interest/financial disclosures
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ORCID 0000-0002-6394-7168
0000-0002-9444-9524
0000-0002-2796-5676
OpenAccessLink https://proxy.k.utb.cz/login?url=https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fmds.29358
PMID 36847308
PQID 2824577386
PQPubID 1016421
PageCount 24
ParticipantIDs proquest_miscellaneous_2780483407
proquest_journals_2824577386
pubmed_primary_36847308
crossref_citationtrail_10_1002_mds_29358
crossref_primary_10_1002_mds_29358
wiley_primary_10_1002_mds_29358_MDS29358
PublicationCentury 2000
PublicationDate May 2023
2023-05-00
20230501
PublicationDateYYYYMMDD 2023-05-01
PublicationDate_xml – month: 05
  year: 2023
  text: May 2023
PublicationDecade 2020
PublicationPlace Hoboken, USA
PublicationPlace_xml – name: Hoboken, USA
– name: United States
– name: Hoboken
PublicationTitle Movement disorders
PublicationTitleAlternate Mov Disord
PublicationYear 2023
Publisher John Wiley & Sons, Inc
Wiley Subscription Services, Inc
Publisher_xml – name: John Wiley & Sons, Inc
– name: Wiley Subscription Services, Inc
References 2017; 5
2021; 429
2019; 7
2019; 9
1996; 39
2012; 124
2019; 10
2015; 125
2019; 12
2015; 30
2015; 11
2020; 80
2016; 31
2014; 69
2019; 103
2014; 29
2020; 146
2020; 32
2017; 595
2018; 44
2013; 260
2014; 130
2016; 79
2021; 38
2021; 15
2020; 2020
2021; 11
2020; 95
2015; 84
2020; 94
2015; 63
2021; 131
2020; 23
2022; 10
2020; 21
2020; 65
2018; 33
2022; 16
e_1_2_8_28_1
e_1_2_8_29_1
e_1_2_8_24_1
e_1_2_8_25_1
e_1_2_8_26_1
e_1_2_8_27_1
e_1_2_8_3_1
e_1_2_8_2_1
e_1_2_8_5_1
e_1_2_8_4_1
e_1_2_8_7_1
e_1_2_8_6_1
e_1_2_8_9_1
e_1_2_8_8_1
e_1_2_8_20_1
e_1_2_8_21_1
e_1_2_8_42_1
e_1_2_8_22_1
e_1_2_8_23_1
e_1_2_8_41_1
e_1_2_8_40_1
e_1_2_8_17_1
e_1_2_8_18_1
e_1_2_8_39_1
e_1_2_8_19_1
e_1_2_8_13_1
e_1_2_8_36_1
e_1_2_8_14_1
e_1_2_8_35_1
e_1_2_8_15_1
e_1_2_8_38_1
e_1_2_8_16_1
e_1_2_8_37_1
e_1_2_8_32_1
e_1_2_8_10_1
e_1_2_8_31_1
e_1_2_8_11_1
e_1_2_8_34_1
e_1_2_8_12_1
e_1_2_8_33_1
e_1_2_8_30_1
References_xml – volume: 131
  issue: 13
  year: 2021
  article-title: Neurodegenerative disorders and gut‐brain interactions
  publication-title: J Clin Investig
– volume: 16
  year: 2022
  article-title: Topography and distribution of adenosine A2A and dopamine D2 receptors in the human subthalamic nucleus
  publication-title: Front Neurosci
– volume: 29
  start-page: 1010
  issue: 8
  year: 2014
  end-page: 1018
  article-title: Multiple organ involvement by alpha‐synuclein pathology in Lewy body disorders
  publication-title: Mov Disord
– volume: 260
  start-page: 1332
  issue: 5
  year: 2013
  end-page: 1338
  article-title: Gastrointestinal manifestations in Parkinson's disease: prevalence and occurrence before motor symptoms
  publication-title: J Neurol
– volume: 69
  start-page: 76
  year: 2014
  end-page: 92
  article-title: Intracellular processing of disease‐associated α‐synuclein in the human brain suggests prion‐like cell‐to‐cell spread
  publication-title: Neurobiol Dis
– volume: 429
  year: 2021
  article-title: Alpha‐synuclein pathology and enteric glia in advanced Parkinson's disease: a study from gastrointestinal biopsies
  publication-title: J Neurol Sci
– volume: 130
  start-page: 805
  issue: 6
  year: 2014
  end-page: 815
  article-title: Enteric GFAP expression and phosphorylation in Parkinson's disease
  publication-title: J Neurochem
– volume: 146
  year: 2020
  article-title: How specific are the conformation‐specific α‐synuclein antibodies? Characterization and validation of 16 α‐synuclein conformation‐specific antibodies using well‐characterized preparations of α‐synuclein monomers, fibrils and oligomers with distinct struct
  publication-title: Neurobiol Dis
– volume: 63
  start-page: 229
  issue: 2
  year: 2015
  end-page: 241
  article-title: Heterogeneity and phenotypic plasticity of glial cells in the mammalian enteric nervous system
  publication-title: Glia
– volume: 38
  start-page: 2854
  issue: 6
  year: 2021
  end-page: 2890
  article-title: The long‐term impact of levodopa/carbidopa intestinal gel on ‘off’‐time in patients with advanced Parkinson's disease: a systematic review
  publication-title: Adv Ther
– volume: 30
  start-page: 517
  year: 2015
  end-page: 524
  article-title: In vivo gastric detection of α‐synuclein inclusions in Parkinson's disease
  publication-title: Mov Disord
– volume: 95
  start-page: e1267
  issue: 9
  year: 2020
  end-page: e1284
  article-title: In vivo distribution of α‐synuclein in multiple tissues and biofluids in Parkinson disease
  publication-title: Neurology
– volume: 80
  start-page: 82
  year: 2020
  end-page: 88
  article-title: No enhanced (p‐) α‐synuclein deposition in gastrointestinal tissue of Parkinson's disease patients
  publication-title: Parkinsonism Relat Disord
– volume: 103
  start-page: 627
  issue: 4
  year: 2019
  end-page: 41.e7
  article-title: Transneuronal propagation of pathologic α‐synuclein from the gut to the brain models Parkinson's disease
  publication-title: Neuron
– volume: 94
  start-page: 481
  issue: 11
  year: 2020
  end-page: 494
  article-title: Disease modification and biomarker development in Parkinson disease
  publication-title: Neurology
– volume: 39
  start-page: 681
  issue: 6
  year: 1996
  end-page: 685
  article-title: A constipation scoring system to simplify evaluation and management of constipated patients
  publication-title: Dis Colon Rectum
– volume: 15
  year: 2021
  article-title: 3D reconstruction of the morpho‐functional topography of the human vagal trigone
  publication-title: Front Neuroanat
– volume: 595
  start-page: 557
  issue: 2
  year: 2017
  end-page: 570
  article-title: Enteric glia: the most alimentary of all glia
  publication-title: J Physiol
– volume: 65
  start-page: 2155
  issue: 6
  year: 2020
  end-page: 2159
  article-title: High‐quality digital 3D reconstruction of microscopic findings in forensic pathology: the terminal pathway of a heart stab wound*
  publication-title: J Forensic Sci
– volume: 5
  start-page: 1
  issue: 1
  year: 2017
  article-title: Distinct pattern of enteric phospho‐alpha‐synuclein aggregates and gene expression profiles in patients with Parkinson's disease
  publication-title: Acta Neuropathol Commun
– volume: 33
  start-page: 1366
  issue: 8
  year: 2018
  end-page: 1368
  article-title: α‐Synuclein antibody 5G4 identifies manifest and prodromal Parkinson's disease in colonic mucosa
  publication-title: Mov Disord
– volume: 84
  start-page: 609
  issue: 6
  year: 2015
  end-page: 616
  article-title: Colonic mucosal α‐synuclein lacks specificity as a biomarker for Parkinson disease
  publication-title: Neurology
– volume: 2020
  start-page: 1
  year: 2020
  end-page: 8
  article-title: Detection of phosphorylated alpha‐synuclein in the muscularis propria of the gastrointestinal tract is a sensitive predictor for Parkinson's disease
  publication-title: Parkinson's Dis
– volume: 10
  year: 2022
  article-title: Infrapatellar fat pad‐synovial membrane anatomo‐functional unit: microscopic basis for Piezo1/2 mechanosensors involvement in osteoarthritis pain
  publication-title: Front Cell Dev Biol
– volume: 21
  issue: 23
  year: 2020
  article-title: Enteric glia at the crossroads between intestinal immune system and epithelial barrier: implications for Parkinson disease
  publication-title: Int J Mol Sci
– volume: 32
  issue: 1
  year: 2020
  article-title: The gut in Parkinson's disease: bottom‐up, top‐down, or neither?
  publication-title: Neurogastroenterol Motil
– volume: 31
  start-page: 241
  issue: 2
  year: 2016
  end-page: 249
  article-title: Alpha‐synuclein in gastric and colonic mucosa in Parkinson's disease: limited role as a biomarker
  publication-title: Mov Disord
– volume: 23
  start-page: 327
  issue: 3
  year: 2020
  end-page: 336
  article-title: Gut‐seeded α‐synuclein fibrils promote gut dysfunction and brain pathology specifically in aged mice
  publication-title: Nat Neurosci
– volume: 11
  start-page: 455
  year: 2021
  end-page: 474
  article-title: The α‐synuclein origin and connectome model (SOC model) of Parkinson's disease: explaining motor asymmetry, non‐motor phenotypes, and cognitive decline
  publication-title: J Parkinsons Dis
– volume: 9
  start-page: S281
  issue: s2
  year: 2019
  end-page: S295
  article-title: Brain‐first versus gut‐first Parkinson's disease: a hypothesis
  publication-title: J Parkinsons Dis
– volume: 79
  start-page: 940
  issue: 6
  year: 2016
  end-page: 949
  article-title: Pathological α‐synuclein in gastrointestinal tissues from prodromal Parkinson disease patients
  publication-title: Ann Neurol
– volume: 21
  issue: 22
  year: 2020
  article-title: Alpha‐synuclein in the gastrointestinal tract as a potential biomarker for early detection of Parkinson's disease
  publication-title: Int J Mol Sci
– volume: 12
  start-page: 139
  issue: 3
  year: 2019
  end-page: 151
  article-title: Modeling α‐synuclein propagation with preformed fibril injections
  publication-title: J Mov Disord
– volume: 2020
  start-page: 1
  year: 2020
  end-page: 13
  article-title: The enteric nervous system and its emerging role as a therapeutic target
  publication-title: Gastroenterol Res Pract
– volume: 10
  start-page: 812
  issue: 2
  year: 2019
  end-page: 823
  article-title: Alpha‐synuclein in peripheral tissues in Parkinson's disease
  publication-title: ACS Chem Nerosci
– volume: 44
  start-page: 722
  issue: 7
  year: 2018
  end-page: 736
  article-title: Detection of alpha‐synuclein conformational variants from gastro‐intestinal biopsy tissue as a potential biomarker for Parkinson's disease
  publication-title: Neuropathol Appl Neurobiol
– volume: 11
  start-page: 625
  issue: 11
  year: 2015
  end-page: 636
  article-title: Pathogenesis of Parkinson disease—the gut–brain axis and environmental factors
  publication-title: Nat Rev Neurol
– volume: 7
  issue: 1
  year: 2019
  article-title: Unique α‐synuclein pathology within the amygdala in Lewy body dementia: implications for disease initiation and progression
  publication-title: Acta Neuropathol Commun
– volume: 125
  start-page: 918
  issue: 3
  year: 2015
  end-page: 925
  article-title: Emerging roles for enteric glia in gastrointestinal disorders
  publication-title: J Clin Investig
– volume: 124
  start-page: 37
  issue: 1
  year: 2012
  end-page: 50
  article-title: An antibody with high reactivity for disease‐associated α‐synuclein reveals extensive brain pathology
  publication-title: Acta Neuropathol
– volume: 30
  start-page: 494
  issue: 4
  year: 2015
  end-page: 498
  article-title: Enteric glial cells: new players in Parkinson's disease?
  publication-title: Mov Disord
– ident: e_1_2_8_7_1
  doi: 10.1212/wnl.0000000000010404
– ident: e_1_2_8_39_1
  doi: 10.1002/mds.26473
– ident: e_1_2_8_13_1
  doi: 10.1155/2020/8024171
– ident: e_1_2_8_11_1
  doi: 10.1002/mds.25776
– ident: e_1_2_8_20_1
  doi: 10.1016/j.parkreldis.2020.08.020
– ident: e_1_2_8_24_1
  doi: 10.1007/s00401-012-0964-x
– ident: e_1_2_8_22_1
  doi: 10.1002/mds.27380
– ident: e_1_2_8_33_1
  doi: 10.1007/bf02056950
– ident: e_1_2_8_28_1
  doi: 10.1113/jp271021
– ident: e_1_2_8_42_1
  doi: 10.1002/glia.22746
– ident: e_1_2_8_37_1
  doi: 10.3389/fcell.2022.886604
– ident: e_1_2_8_19_1
  doi: 10.1111/nan.12486
– ident: e_1_2_8_16_1
  doi: 10.1111/nmo.13777
– ident: e_1_2_8_30_1
  doi: 10.1002/mds.25979
– ident: e_1_2_8_9_1
  doi: 10.1002/mds.25988
– ident: e_1_2_8_15_1
  doi: 10.3233/JPD-191721
– ident: e_1_2_8_41_1
  doi: 10.1016/j.jns.2021.119460
– ident: e_1_2_8_36_1
  doi: 10.3389/fnins.2022.945574
– ident: e_1_2_8_2_1
  doi: 10.1038/nrneurol.2015.197
– ident: e_1_2_8_23_1
  doi: 10.1016/j.nbd.2014.05.020
– ident: e_1_2_8_25_1
  doi: 10.1016/j.nbd.2020.105086
– ident: e_1_2_8_3_1
  doi: 10.1016/j.neuron.2019.05.035
– ident: e_1_2_8_5_1
  doi: 10.1007/s00415-012-6801-2
– ident: e_1_2_8_12_1
  doi: 10.1172/jci143775
– ident: e_1_2_8_18_1
  doi: 10.1155/2020/4687530
– ident: e_1_2_8_38_1
  doi: 10.1212/wnl.0000000000001240
– ident: e_1_2_8_35_1
  doi: 10.3389/fnana.2021.663399
– ident: e_1_2_8_4_1
  doi: 10.14802/jmd.19046
– ident: e_1_2_8_29_1
  doi: 10.1111/jnc.12742
– ident: e_1_2_8_21_1
  doi: 10.3390/ijms21228666
– ident: e_1_2_8_14_1
  doi: 10.3233/JPD-202481
– ident: e_1_2_8_6_1
  doi: 10.1212/wnl.0000000000009107
– ident: e_1_2_8_26_1
  doi: 10.1186/s40478-019-0787-2
– ident: e_1_2_8_34_1
  doi: 10.1111/1556-4029.14497
– ident: e_1_2_8_31_1
  doi: 10.3390/ijms21239199
– ident: e_1_2_8_8_1
  doi: 10.1021/acschemneuro.8b00383
– ident: e_1_2_8_10_1
  doi: 10.1186/s40478-016-0408-2
– ident: e_1_2_8_27_1
  doi: 10.1172/jci76303
– ident: e_1_2_8_17_1
  doi: 10.1002/ana.24648
– ident: e_1_2_8_32_1
  doi: 10.1007/s12325-021-01747-1
– ident: e_1_2_8_40_1
  doi: 10.1038/s41593-020-0589-7
SSID ssj0011516
Score 2.5436566
Snippet Background The role of the gut‐brain axis has been recently highlighted as a major contributor to Parkinson's disease (PD) physiopathology, with numerous...
The role of the gut-brain axis has been recently highlighted as a major contributor to Parkinson's disease (PD) physiopathology, with numerous studies...
BackgroundThe role of the gut‐brain axis has been recently highlighted as a major contributor to Parkinson's disease (PD) physiopathology, with numerous...
SourceID proquest
pubmed
crossref
wiley
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 885
SubjectTerms alpha-Synuclein - metabolism
alpha‐synuclein
Antibodies
Biopsy
Cell size
Duodenum
Duodenum - chemistry
Duodenum - metabolism
Duodenum - pathology
Endoscopy
Enteric nervous system
gastrointestinal biopsies
Glial cells
Glial fibrillary acidic protein
Glial Fibrillary Acidic Protein - metabolism
Gliosis
Gut-brain axis
Humans
Immunohistochemistry
Levodopa
Movement disorders
Neurodegenerative diseases
Neuronal-glial interactions
neuropathology
Ostomy
Parkinson Disease - pathology
Parkinson's disease
Pathology
Proteins
Small intestine
Synuclein
Tubulin
Title Duodenal alpha‐Synuclein Pathology and Enteric Gliosis in Advanced Parkinson's Disease
URI https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fmds.29358
https://www.ncbi.nlm.nih.gov/pubmed/36847308
https://www.proquest.com/docview/2824577386
https://www.proquest.com/docview/2780483407
Volume 38
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LT9wwEB4BB9QLrxZYXnIRUrlkSeIkG6snxBYQEhWCIu2hUjR2bGnVbRaR3QOc-An8Rn5Jx84D0YKEeokiefKyPa_MzDcAe4mNbZk08WLZU7YkR3ipRPRQxhy5UJhol-X7PTm9js4G8WAGvja1MBU-RPvDzXKGk9eWwVGWB8-gob_zshvaKB7JX5urZQ2iyxY6igwd1_aUmCh2FcINqpAfHrRXvtRF_xiYL-1Vp3COF-Fn86pVnsmv7nQiu-r-LxTH__yWJVioDVF2WO2cZZjRxQrMn9eh9o8w6E_HJJOIxJXjPj08Xt0VFvx4WLALnDihecewyJnLKxgqdjIajsthyYjgsM4sYLao2tWXfSlZv4oFfYLr428_jk69ug2Dpzj5x3TMe0GkDHLjS0EuhjDklUmRmyCVvcSkETlZOlIcAxOF1mbwjdACVY6KyARfhbliXOh1YDE3OjTGzwOjSBHmiLkOjG2ZxbUIETuw3yxIpmqMctsqY5RV6MphRjOVuZnqwG5LelMBc7xGtNWsalbzJo2kYRT3bLPTDnxuh4mrbKgECz2eEo3FZUo5ebsdWKt2Q_sUnpBG5z7dfN-t6duPz877V-5k4_2km_DBdrSvciq3YG5yO9XbZPdM5A7MhtHFjtvmfwAA3__X
linkProvider Wiley-Blackwell
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1fT9swED9BJw1eYBsDCh3zJqT1JW0SJ2ks7QWtdOVPq4m2Ul9Q5Di2VFFSRNuH8rSPsM-4T7Kz82dibNLESxTJlzixfb47393vAI4D7dtSYWD5cUvolBxmhTHnFo99yikTPJAmyrcfdEfe-dgfr8HnIhcmw4coD9w0Z5j9WjO4PpBu_kYNvU3mDVe78dbhha7obQyqqxI8ClUdU_gU2cg3OcIFrpDtNstHH0ujJyrmY43ViJzONlwXH5tFmtw0lou4IR7-wHF87t-8gq1cFyUn2eJ5DWsyfQMve7m3fQfG7eUMtyUkMRm5P7__GKxSjX88Sck3vjD75orwNCEmtGAiyNfpZDafzAkSnOTBBUTnVZsUs09z0s7cQW9h1DkdfulaeSUGS1A0kfGatBxPKE6VHTO0MphCwyxmiXLCuBWo0EM7S3qCckd5rlYbbMUk4yLhAskY3YVKOkvlPhCfKukqZSeOEigLE84T6ShdNYtK5nJehXoxI5HIYcp1tYxplAEsuxGOVGRGqgofS9K7DJvjb0S1YlqjnD2xJXQ9v6XrnVbhQ9mMjKW9JTyVsyXSaGimkKLBW4W9bDmUvdAAhTq18eV1M6n_7j7qtQfm5uD_Sd_DRnfYu4wuz_oXh7CpC9xnIZY1qCzul_IdqkGL-Mis9l_n4gMq
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1La9tAEB4cF0Iu6SsPt267LYHmIkfSSrKWnkxVN20aY_IAHwJitQ8wcWRT2wfnlJ_Q39hf0tnVI7htoPQiBDt67c7szGhmvgE4iExsS8eRE2ZdYUpymBNnnDs8CymnTPBI2SzfQXR8GXwdhaMGfKhqYQp8iPqHm5EMu18bAZ9JfXQPGnoj5x3fRPE24FEQubFh6eSsxo5CS8f2PUUpCm2JcAUr5PpH9aXryugPC3PdYLUap_8Yrqp3LRJNrjvLRdYRt7_BOP7nxzyB7dISJb2CdZ5CQ-XPYPO0jLU_h1GynOKmhCS2Hvfn3Y_zVW7Qj8c5GfKF3TVXhOeS2MSCsSCfJ-PpfDwnSNArUwuIqaq2BWbv5yQpgkE7cNn_dPHx2Cn7MDiCooOMR9n1AqE51W7G0MdgGt2yjEntxVk30nGAXpYKBOWeDnxjNLiaKcaF5ALJGN2FZj7N1T6QkGrla-1KTwvUhJJzqTxtemZRxXzOW3BYLUgqSpBy0ytjkhbwyn6KM5XamWrBu5p0ViBz_I2oXa1qWgonjsR-EHZNt9MWvK2HUaxMrITnarpEGgPMFFN0d1uwV3BD_RQaoUqnLt780K7pw49PT5Nze_Li30nfwOYw6affvgxOXsKW6W5f5Fe2obn4vlSv0AZaZK8tr_8C_m4B4g
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Duodenal+alpha-Synuclein+Pathology+and+Enteric+Gliosis+in+Advanced+Parkinson%27s+Disease&rft.jtitle=Movement+disorders&rft.au=Emmi%2C+Aron&rft.au=Sandre%2C+Michele&rft.au=Russo%2C+Francesco+Paolo&rft.au=Tombesi%2C+Giulia&rft.date=2023-05-01&rft.issn=1531-8257&rft.eissn=1531-8257&rft.volume=38&rft.issue=5&rft.spage=885&rft_id=info:doi/10.1002%2Fmds.29358&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0885-3185&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0885-3185&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0885-3185&client=summon